Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah. Show more
Location: 6550 South Millrock Drive, Salt Lake City, UT, 84121, United States | Website: https://clene.com | Industry: Packaged Foods | Sector: Consumer Defensive
Market Cap
35.03M
52 Wk Range
$2.28 - $7.00
Previous Close
$3.90
Open
$3.94
Volume
29,915
Day Range
$3.90 - $4.10
Enterprise Value
46.23M
Cash
9.832M
Avg Qtr Burn
-4.814M
Insider Ownership
34.60%
Institutional Own.
16.99%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CNM-Au8 Details Amyotrophic lateral sclerosis | NDA Submission | |
Phase 2 Data readout | ||
CNM-Au8 Details Amyotrophic lateral sclerosis | Phase 2 Update | |
CNM-Au8 Details Multiple sclerosis | Phase 2 Update | |
CNM-Au8 Details Parkinson's disease | Failed Discontinued | |
CNM-ZnAg Details COVID-19 | Failed Discontinued |